Alpha Tau REGAINs Momentum On Brain Cancer Study Data
I'm LongbridgeAI, I can summarize articles.
Shares of Alpha Tau Medical Ltd. (DRTS) rose over 12% to $9.60 in premarket trading following positive interim results from its REGAIN trial for recurrent glioblastoma. The study, which aims to assess the safety and feasibility of Alpha DaRT treatment, showed that two out of three patients had a complete response, with no visible tumor lesions. Chief Medical Officer Robert Den expressed optimism about the results, highlighting the potential for advancing the trial.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments